“`html
Artificial intelligence (AI) is quietly revolutionizing healthcare, and a surprising early win may lie in streamlining the 340B Drug Pricing Program. A new study shows AI can prescreen patients for clinical trials wiht accuracy rates rivaling-and sometimes exceeding-human reviewers, a capability that could translate to meaningful efficiency gains for the 340B program.
Created by Congress in 1992,the 340B program helps eligible healthcare organizations-like safety-net hospitals and clinics-access outpatient drugs at reduced prices. According to the Health Resources and Services Administration (HRSA), the program’s goal is to maximize limited federal funds, expanding patient access and bolstering services for underserved communities.1
AI’s potential to streamline operations mirrors this core mission. Consider clinical trial recruitment,where efficiency and precision are paramount. Researchers developed RECTIFIER, a system powered by GPT-4, to prescreen patients and assess their eligibility.The results are compelling.
In a study focused on heart failure trials
